PULMONARY ARTERIAL HYPERTENSION · White paper
Pulmonary Arterial Hypertension (PAH) - Trial-design focus
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About pulmonary arterial hypertension (pah) - trial-design focus — and why its trials are hard
Pulmonary arterial hypertension (WHO Group 1) is a rare, progressive vasculopathy defined hemodynamically by elevated mean pulmonary arterial pressure with normal wedge pressure and raised pulmonary vascular resistance, confirmed by right heart catheterization. Because PAH is rare and highly heterogeneous, trial design is a central determinant of success: small recruitable populations, high mortality that can truncate studies, and variable disease trajectories all constrain statistical power. Historically the 6-minute walk distance (6MWD) served as the workhorse functional endpoint, but regulators and sponsors have shifted toward composite time-to-clinical-worsening (TTCW) and morbidity-mortality endpoints, as validated in event-driven trials like SERAPHIN and GRIPHON. Modern PAH trials increasingly combine functional, hemodynamic, and biomarker readouts (6MWD, PVR, NT-proBNP), integrate adaptive designs (as in the sotatercept PULSAR study), and use patient stratification by subtype and risk. The 2024 approval of sotatercept (Winrevair) via STELLAR illustrates the value of multi-domain composite endpoints and adaptive planning.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Bosentan (Tracleer) | 2001 | PAH, WHO functional class II-IV (dual endothelin receptor antagonist) | BREATHE-1 | 6-minute walk distance; time to clinical worsening | Placebo-adjusted 6MWD +44 m; event-free rate 89% vs 63% placebo |
| Sildenafil (Revatio) | 2005 | PAH (PDE-5 inhibitor) | SUPER-1 | Change from baseline in 6MWD | 6MWD increase of ~45-50 m across doses vs placebo at 12 weeks |
| Ambrisentan (Letairis) | 2007 | PAH, WHO Group 1 (selective endothelin-A receptor antagonist) | ARIES-1 & ARIES-2 | 6MWD; time to clinical worsening | Placebo-adjusted 6MWD +31 to +59 m; TTCW HR ~0.28-0.30 |
| Macitentan (Opsumit) | 2013 | PAH (endothelin receptor antagonist), event-driven design | SERAPHIN | Composite morbidity-mortality (TTCW) | 45% reduction in morbidity/mortality risk (HR 0.55, p<0.0001; n=742) |
| Selexipag (Uptravi) | 2015 | PAH (oral selective IP prostacyclin receptor agonist), event-driven | GRIPHON | Composite morbidity-mortality event | 40% reduction in first morbidity-mortality event (HR 0.60, p<0.0001; n=1,156) |
| Sotatercept (Winrevair) | 2024 | PAH, WHO Group 1 add-on (first-in-class activin signaling inhibitor) | STELLAR | Change in 6MWD; multi-component secondary (PVR, NT-proBNP, TTCW) | Significant placebo-corrected 6MWD improvement plus benefit across PVR and NT-proBNP |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in pulmonary arterial hypertension (pah) - trial-design focus development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Imatinib — IMPRES | Improved hemodynamics but not adopted; serious adverse events including subdural hematomas and high dropout | Safety burden and inability to reverse vascular remodeling; oncology-drug repurposing challenge |
| Sitaxentan — STRIDE-1 / STRIDE-2 | Withdrawn from market due to severe hepatotoxicity | Fatal liver toxicity outweighed endothelin-antagonist efficacy |
| Seralutinib — TORREY | Interim analysis showed insufficient efficacy | Inadequate efficacy signal on primary endpoint at interim (per white paper) |
Choosing the right endpoint
Primary endpoints that matter in pulmonary arterial hypertension (pah) - trial-design focus trials
- 6-Minute Walk Distance (6MWD) — Most frequently used functional endpoint; simple and reproducible but influenced by patient effort and comorbidities, and modest changes may not capture long-term outcome
- Time to Clinical Worsening (TTCW) — Composite of death, hospitalization, and disease progression; requires a standardized, prospectively agreed definition to ensure cross-trial comparability
- Composite morbidity-mortality endpoint — Event-driven primary endpoint (e.g., SERAPHIN, GRIPHON) now favored by regulators over 6MWD alone for demonstrating durable clinical benefit
- Pulmonary Vascular Resistance (PVR) — Hemodynamic measure of pulmonary arterial resistance; reductions signify improved flow but require invasive right heart catheterization
- NT-proBNP — Biomarker of right ventricular strain used as a supportive/surrogate endpoint; best interpreted alongside functional and hemodynamic measures
How iNGENū runs pulmonary arterial hypertension (pah) - trial-design focus trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Pulmonary Arterial Hypertension (PAH) - Trial-design focus clinical trials — FAQs
Why has PAH trial design moved beyond 6MWD?
How do adaptive designs help in a rare disease like PAH?
What role do biomarkers and composite endpoints play?
Ready to discuss your pulmonary arterial hypertension (pah) - trial-design focus trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal